International Journal of Infection

Published by: Kowsar

Sustained Virological Response After Six Weeks Treatment with a Sofosbuvir-Containing Regimen in a Patient Infected with Hepatitis C Virus Genotype 4: A Case Report

Nawfal R Hussein 1 , *
Author Information
1 Department of Internal Medicine, College of Medicine, University of Duhok, Duhok, Iraq
Article information
  • International Journal of Infection: July 2017, 4 (3); e41216
  • Published Online: August 28, 2016
  • Article Type: Case Report
  • Received: August 2, 2016
  • Accepted: August 4, 2016
  • DOI: 10.5812/iji.41216

To Cite: Hussein N R. Sustained Virological Response After Six Weeks Treatment with a Sofosbuvir-Containing Regimen in a Patient Infected with Hepatitis C Virus Genotype 4: A Case Report, Int J Infect. 2017 ; 4(3):e41216. doi: 10.5812/iji.41216.

Abstract
Copyright © 2016, Infectious Diseases and Tropical Medicine Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Case Presentation
3. Discussion
Footnote
References
  • 1. Hussein NR. Prevalence of HBV, HCV and HIV and Anti-HBs antibodies positivity in healthcare workers in departments of surgery in Duhok city, Kurdistan region, Iraq. Int J Pure Appl Sci Technol. 2015; 26(6): 70-5
  • 2. Averhoff FM, Glass N, Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis. 2012; 55 Suppl 1-5[DOI][PubMed]
  • 3. Koshy A, Madda JP, Marcellin P, Martinot M. Treatment of hepatitis C virus genotype 4-related cirrhosis: ribavirin and interferon combination compared with interferon alone. J Clin Gastroenterol. 2002; 35(1): 82-5[PubMed]
  • 4. Legrand-Abravanel F, Colson P, Leguillou-Guillemette H, Alric L, Ravaux I, Lunel-Fabiani F, et al. Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. J Med Virol. 2009; 81(12): 2029-35[DOI][PubMed]
  • 5. Hussein NR, Saleem ZS. Successful Treatment of Hepatitis C Virus Genotype 4 in Renal Transplant Recipients With Direct-Acting Antiviral Agents. Am J Transplant. 2016; 16(7): 2237-8[DOI][PubMed]
  • 6. Yilmaz H, Yilmaz EM, Leblebicioglu H. Barriers to access to hepatitis C treatment. J Infect Dev Ctries. 2016; 10(4): 308-16[DOI][PubMed]
  • 7. Hussein NR, Tunjel I, Basharat Z, Taha A, Irving W. The treatment of HCV in patients with haemoglobinopathy in Kurdistan Region, Iraq: a single centre experience. Epidemiol Infect. 2016; 144(8): 1634-40[DOI][PubMed]
  • 8. Vespasiani-Gentilucci U, Galati G, Gallo P, De Vincentis A, Riva E, Picardi A. Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens. World J Gastroenterol. 2015; 21(24): 7412-26[DOI][PubMed]
  • 9. Hussein NR. Sofosbuvir-containing regimen for the treatment of hepatitis c virus in a patient with sickle-thalassemia: A first case report. Int J Infect. 2016;
  • 10. Hussein NR, Saleem ZSM. Successful treatment of Hepatitis C virus infection in a renal transplant patient with ribavirin and sofosbuvir: A case report. Int J Case Rep Imag. 2016; 7
  • 11. Mihaila RG, Cipaian RC. Eltrombopag in chronic hepatitis C. World J Gastroenterol. 2014; 20(35): 12517-21[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments